معرفی
Neil Rickman is Professor of Economics at the University of Surrey, where he has served since 1995 and as Head of Department from 2004-2009. He currently serves on the Economics and Econometrics REF 2020 sub-panel and as Associate Editor of the International Review of Law and Economics. Previously, he was Visiting Professor at Erasmus University Rotterdam (2011-2015) and held executive roles with the Royal Economic Society (2007-2018).
His educational background includes:
- BA (Hons) Economics, University of Durham (1988)
- PhD Economics, McGill University (1995)
Professor Rickman's research centers on Law and Economics with dual specializations in Health Economics and Regulation Theory. He applies bargaining theory and principal-agent frameworks to analyze medical negligence systems, legal aid reform, and energy market structures. His work demonstrates how economic incentives shape litigation behavior, patient safety outcomes, and regulatory effectiveness in complex institutional environments. Notable contributions include establishing fixed recoverable costs regimes in English personal injury litigation.
His publication record reveals consistent thematic evolution from foundational work in spectrum regulation toward contemporary applications in pandemic economics and labor contract design. The research trajectory shows increasing integration of health policy with legal economics, particularly in NHS contract analysis and medical error prevention.
His scientific recognition includes:
- Fellow of the Royal Economic Society (2025)
Professor Rickman has provided influential policy advice to multiple UK government bodies:
- Legal Sector: Department of Constitutional Affairs, Ministry of Justice, Legal Services Commission, Law Society, Civil Justice Council
- Health Sector: Department of Health on medical negligence systems
- Regulatory Agencies: Ofcom on spectrum regulation
He maintains active policy engagement through REF 2020 participation and continues to advise on legal-health system intersections, particularly regarding MRSA infection control and clinical negligence funding mechanisms.
